# Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors

> **NCT02746081** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 81 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** BAY1436032

## Key facts

- **NCT ID:** NCT02746081
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-26
- **Primary completion:** 2018-11-08
- **Final completion:** 2024-12-03
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02746081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02746081, "Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT02746081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*